Five patients with haemorrhagic thrombosis and low platelet counts admitted to Oslo University Hospital after vaccination with AstraZeneca have previously been reported. One died earlier this week, now there have been two more deaths.
These cases could be related to AstraZeneca
The Norwegian Medicines Agency cannot rule out that these cases may be related to AstraZeneca. EMA's Safety Committee (PRAC) decided that such cases will now be described in the description of the medicinal product and in the package leaflet.
The Norwegian Medicines Agency reports all cases in Norway
The Norwegian Medicines Agency and the European Medicines Agency (EMA) continue to review similar reports of side effects in Europe to see if these cases could be related to vaccination with AstraZeneca. The Medicines Agency reports all cases in Norway to the European Medicines Agency (EMA) and WHO.
Collaboration in researching all these cases
The unusual picture of the disease with blood clots, bleeding and low platelet counts has not been seen after vaccination with the other Covid-19 vaccines used in Norway. The Norwegian Medicines Agency, the National Institute of Public Health and the University Hospital of Oslo are currently collaborating on a thorough study of these cases.
These are two tragic deaths among patients
- These are two tragic deaths among patients who have been admitted with a particular combination of blood clots, bleeding and low platelet count. We have been informed that both of them have died today, says Steinar Madsen and the Norwegian Medicines Agency.
Norway has suspended vaccination with AstraZeneca
Recall that Norway has suspended vaccination with AstraZeneca following reports of a rare course of the disease in some people who received this vaccine.
